Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
In a new research report, Deutsche Bank analysts suggest investors focus on sectors like technology, health care, financials and selected industrials.
A new research report from Merrill Lynch highlights 10 top catalyst-driven ideas for the fourth quarter.
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
A new research report from UBS focuses on four top companies that are making great strides in treatments for patients -- and generating gigantic revenues.
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy for the rest of this year and 2015, and the analysts keep…
Jon OggStocks were firm yet again on Friday morning ahead of the PPI wholesale inflation report. Investors have been trying to decide where to put their money after the recent stock market…
Jon OggStocks were firm on Monday morning, looking to add to the recovery bounce from Friday. Investors have now been given an opportunity to look for stocks that have pulled back that…
In a new report from Oppenheimer, analysts combine their fundamental rating on a company of Outperform with positive earnings revisions, and then toss in a bullish technical profile for good measure.
ThinkstockA brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The analysts screened…
An new report from Credit Suisse highlights the stocks where large-cap fund managers have been placing new bets the most. We screened those stocks for ones rated Outperform at Credit Suisse.
bfishshadow via Wikimedia CommonsShort sellers shied away from four of the top five most shorted stocks on the Nasdaq between the June 30 and July 15 settlement dates. The outlier was Frontier…
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) has now reported its second-quarter earnings. The largest biotech by market cap turned in earnings of $2.36 per share ($3.93 billion) on more than a 100% gain…
Jon C. Ogg ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will change during…
